Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

NCT03328364 is registered in ClinicalTrials.gov with Astellas Pharma a/s as lead sponsor.

NCT NCT03328364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03328364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Lead sponsor
Astellas Pharma a/s
Phase
Observational
Overall status
Completed
Start date
December 1, 2017
Completion date
December 24, 2017
Enrollment
211 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer